Clinical trial • Phase III • Endocrinology
RO7204239 for Type 2 diabetes mellitus | Overweight | Obesity
Phase III trial of RO7204239 for Type 2 diabetes mellitus | Overweight | Obesity. None/Not specified-controlled. 30 participants.
Overview
- Trial Therapeutic Area
- Endocrinology
- Trial Disease
- Type 2 diabetes mellitus | Overweight | Obesity
- Trial Stage
- Phase III
Key dates
- Initial CTIS Submission Date
- 27-05-2025
- First CTIS Authorization Date
- 15-08-2025
Trial design
None/Not specified-controlled Phase III trial across 1 site in Germany.
- Comparator
- None/Not specified
- Target Sample Size
- 30
- Trial Duration For Participant
- 519
Recruitment
- Planned Sample Size
- 30
- Recruitment Window Months
- 17
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 30
Germany
- Earliest CTIS Part Ii Submission Date
- 17-07-2025
- Latest Decision Or Authorization Date
- 08-01-2026
- Processing Time Days
- 175
- Number Of Sites
- 1
- Number Of Participants
- 30
Sites
- Site Name
- PROFIL Institut fuer Stoffwechselforschung GmbH
- Contact Person Name
- Patrick Fischer
- Contact Person Email
- patrick.fischer@profil.com
- Number Of Participants
- 30
Sponsor
Primary sponsor
- Full Name
- F. Hoffmann-La Roche AG
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- Switzerland
Investigational products
- Investigational Product Name
- RO7204239
Related trials
Other published trials that may interest you.